Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue.
Vertex Pharmaceuticals's Degree of Operating Leverage for the quarter that ended in Jun. 2026 was 1.05. The higher Degree of Operating Leverage, the higher operating risk the company will take.
The industry rank for Vertex Pharmaceuticals's Degree of Operating Leverage or its related term are showing as below:
MEX:VRTX's Degree of Operating Leverage is ranked worse than 68.8% of 859
companies
in the Biotechnology industry
Industry Median: -0.01
vs MEX:VRTX: 1.05
Vertex Pharmaceuticals (MEX:VRTX) Degree of Operating Leverage Explanation
Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.
A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.
Be Aware
The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.
Vertex Pharmaceuticals Degree of Operating Leverage Related Terms
Vertex Pharmaceuticals Degree of Operating Leverage Historical Data
* Premium members only.
The historical data trend for Vertex Pharmaceuticals's Degree of Operating Leverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals Degree of Operating Leverage Chart
MEX:VRTX vs REGN, MRNA, RVMD: Degree of Operating Leverage Comparison
For the Biotechnology subindustry, Vertex Pharmaceuticals's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vertex Pharmaceuticals Degree of Operating Leverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Degree of Operating Leverage distribution charts can be found below:
* The bar in red indicates where Vertex Pharmaceuticals's Degree of Operating Leverage falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
What does a Degree of Operating Leverage of 1.05 mean?
Vertex Pharmaceuticals (MEX:VRTX) has a Degree of Operating Leverage of 1.05 as of Jun. 2026. Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. View historical data for Vertex Pharmaceuticals and its competitors. According to the industry distribution chart, Vertex Pharmaceuticals ranks #591 out of 859 companies in the Biotechnology industry, placing it in the top 68.8%.
Is Vertex Pharmaceuticals' Degree of Operating Leverage too high?
Vertex Pharmaceuticals' current Degree of Operating Leverage is 1.05. Based on the distribution chart, Vertex Pharmaceuticals ranks #591 out of 859 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vertex Pharmaceuticals has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Degree of Operating Leverage compare to REGN and MRNA?
According to the Biotechnology industry distribution chart, Vertex Pharmaceuticals ranks #591 out of 859 companies for Degree of Operating Leverage. This places Vertex Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Degree of Operating Leverage for a Biotechnology company?
A good Degree of Operating Leverage depends on the Biotechnology industry context. However, Degree of Operating Leverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Degree of Operating Leverage mean?
A high Degree of Operating Leverage can signal that a stock is expensive relative to its fundamentals. Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. View historical data for Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current Degree of Operating Leverage is 1.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (MEX:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is MXN8,957.40, compared to a current price of MXN8,776.36 — trading 2% below its estimated fair value. The current Degree of Operating Leverage is 1.05. Vertex Pharmaceuticals' overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Degree of Operating Leverage calculated?
Degree of Operating Leverage is calculated from a company's financial statements. For Vertex Pharmaceuticals (MEX:VRTX), the current Degree of Operating Leverage is 1.05 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vertex Pharmaceuticals (MEX:VRTX) Overvalued in 2026?
Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN8,776.36 is trading 2% below its estimated GF Value™ of MXN8,957.40.
GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.
Key valuation signals for MEX:VRTX:
Degree of Operating Leverage: 1.05
GF Value™: MXN8,957.40 vs. price of MXN8,776.36 (2% below fair value)
No single metric tells the full story. See the MEX:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
91GF Score
Get the complete analysis for MEX:VRTX
Degree of Operating Leverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:VRTX has been successfully added to your 
